<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04420624</url>
  </required_header>
  <id_info>
    <org_study_id>7727</org_study_id>
    <nct_id>NCT04420624</nct_id>
  </id_info>
  <brief_title>COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction</brief_title>
  <acronym>COLD-MI</acronym>
  <official_title>COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the benefit of colchicine on induced denervation after myocardial&#xD;
      infarction. Patients who have suffered a documented De Novo myocardial infarction and&#xD;
      completed a revascularization procedure will receive either colchicine on top of standard&#xD;
      therapy, compared to standard therapy alone (1:1 allocation ratio). Colchicine 1mg (or 0.5mg)&#xD;
      will be initiated within 48h after percutaneous revascularization and prescribed for one&#xD;
      month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COLD-MI study aims to explore colchicine's impact on myocardial denervation following&#xD;
      reperfused acute myocardial infarction. Acute myocardial infarction is the leading cause of&#xD;
      heart failure (HF). It induces myocardial denervation predisposing to ventricular rhythm&#xD;
      disorders and death. This denervation linked to infarction's size occurs by direct ischaemic&#xD;
      mechanisms during the initial coronary occlusion (initially non-vascularised zone) and&#xD;
      secondarily by cardiac remodelling in the context of the heart failure (HF). In usual&#xD;
      practice, cardiac denervation which intensity is correlated with rhythm and mortality risks,&#xD;
      can be evaluated by scintigraphy. In a murine reperfusion model of ischemia, the direct&#xD;
      anti-inflammatory effect of colchicine reduces the size of the necrosis and improves&#xD;
      post-ischemic remodeling. This suggests that colchicine may reduce myocardial denervation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, phase IIb, monocentric, randomized, open labeled with 2 parallel study arms.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of myocardial denervation</measure>
    <time_frame>6 month</time_frame>
    <description>assess by MIBG (méta-iodobenzylguanidine)-nuclear cardiac imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the heart-to-mediastinum ratio</measure>
    <time_frame>6 month</time_frame>
    <description>The heart-to-mediastinum (H/M) ratio, the heart count normalized for the mediastinum count, is used as a quantitative index in cardiac 123 I-MIBG imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction in percent</measure>
    <time_frame>6 month</time_frame>
    <description>By transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction in percent</measure>
    <time_frame>6 month</time_frame>
    <description>By MIBG (méta-iodobenzylguanidine)-nuclear cardiac imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction in percent</measure>
    <time_frame>1 month</time_frame>
    <description>By transthoracic echocardiogram (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sinus variability</measure>
    <time_frame>6 month</time_frame>
    <description>by 24 hours holter recording : SDNN (Standard Deviation of NN intervals) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sinus variability</measure>
    <time_frame>1 month</time_frame>
    <description>by 24 hours holter recording : SDNN (Standard Deviation of NN intervals) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (QRS duration)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (QRS duration)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (corrected QT)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic ECG parameters (corrected QT)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular extrasystole (2 or 3 VES) per 24 hours on the Holter</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bursts (2 or 3 VES) per 24 hours on the Holter</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bursts (2 or 3 VES) per 24 hours on the Holter</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular or supraventricular tachycardia (&gt;3 VES) episodes per 24 hours</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular or supraventricular tachycardia (&gt;3 VES) episodes per 24 hours</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to death (total mortality)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to heart failure hospitalization</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to all-cause hospitalization</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of NGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of NGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of proNGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of proNGF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of BDNF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in the levels of neurotrophic molecular markers</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of BDNF ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological evaluation of infarction size Creatine PhosphoKinase (CPK)</measure>
    <time_frame>During hospitalization (Day 1 to Day 5)</time_frame>
    <description>Area Under Curve (AUC) of CPK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological evaluation of infarction size (troponin)</measure>
    <time_frame>During hospitalization (Day 1 to Day 5)</time_frame>
    <description>Area Under Curve (AUC) of Troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of biomarkers from blood : CRP (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of biomarkers from blood : CRP (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between hospitalization and 1 month</time_frame>
    <description>Concentration of biomarkers from blood : sST2 (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post infarction systemic inflammation evaluation</measure>
    <time_frame>Between 1 month and 6 months</time_frame>
    <description>Concentration of biomarkers from blood : sST2 (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size in percentage of left ventricular</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse event</measure>
    <time_frame>from randomization to 6 months</time_frame>
    <description>Comparison of adverse events between 2 arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Myocardial Infarction, Acute</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colchicine and standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month</description>
    <arm_group_label>Colchicine</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age from 18 to 80 year old&#xD;
&#xD;
          -  Hospitalization within 12 hours of onset of acute chest pain&#xD;
&#xD;
          -  Patient must have suffered a documented acute myocardial infarction&#xD;
&#xD;
          -  Coronary occlusion on initial angiography (culprit artery with aTIMI (Thrombolysis in&#xD;
             Myocardial Infarction) flow 1 or 0)&#xD;
&#xD;
          -  Patient eligible for a revascularization procedure by PTCA (Percutaneous transluminal&#xD;
             coronary angioplasty)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of myocardial infarction prior to the current episode&#xD;
&#xD;
          -  Patient in cardiogenic shock or with hemodynamic instability&#xD;
&#xD;
          -  Patients with severe hepatic or renal dysfunction (GFR ≤30 mL/min)&#xD;
&#xD;
          -  Pregnant women or women of childbearing age without contraception&#xD;
&#xD;
          -  Treatment with a potent CYP3A4 inhibitor or a P-glycoprotein inhibitor in patients&#xD;
             with renal or hepatic impairement&#xD;
&#xD;
          -  Association with macrolides (except spiramycin)&#xD;
&#xD;
          -  Association with pristinamycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Sympathetic denervation</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

